Clinical trials
Resectable Non-small Cell Lung Cancer clinical trials
Below are recruiting resectable non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04991025RecruitingPhase 2
Certolizumab added to chemo and nivolumab for operable lung cancer
This Phase 2 study tests whether adding certolizumab (an immune-targeting medicine) to standard chemo plus nivolumab can improve outcomes in people with certain operable non-small cell lung cancers. The goal is to see if this combination works better than standard treatment before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Birmingham, AlabamaAges 18 years+ - NCT05061550RecruitingPhase 2
Targeted immune-plus-chemo treatment before and after lung surgery
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Little Rock, ArkansasAges 18–95 - NCT05104788RecruitingPhase 2
Icotinib plus chemotherapy before surgery for EGFR lung cancer
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
BeijingAges 18–75 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05167487Recruiting
Study of treatment effects after chemotherapy and surgery for lung cancer
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
A Coruña, A CoruñaAges 18 years+ - NCT05211895RecruitingPhase 3
Durvalumab plus domvanalimab after chemoradiation for stage 3 lung cancer
This trial studies whether adding durvalumab and domvanalimab after standard chemoradiation can keep unresectable stage 3 lung cancer from coming back or getting worse. It targets tumors with specific lab test results (including PD-L1 and gene markers).
Chandler, ArizonaAges 18 years+ - NCT05234307RecruitingPhase 1
Nivolumab plus PBF-1129 for advanced lung cancer
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
Columbus, OhioAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT05241028RecruitingPhase 2
Adjuvant ensartinib for ALK-positive lung cancer after surgery
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
Shijiazhuang, HebeiAges 18–75 - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05295212RecruitingPhase 2
Atezolizumab plus chemo before surgery for lung cancer
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Changsha, HunanAges 18 years+ - NCT05334277RecruitingPhase 2
Test furmonertinib for advanced EGFR-mutant lung cancer
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
ChangchunAges 18 years+ - NCT05341583RecruitingPhase 3
Ensartinib after lung cancer surgery for ALK-positive patients
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
TianjinAges 18 years+ - NCT05352035Recruiting
Study tumor evolution in early lung cancer after surgery
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
BeijingAges 18 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05366478RecruitingPhase 1
LM103 for advanced solid tumors using donated immune cells
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
TianjinAges 18 years+ - NCT05377658RecruitingPhase 2
AK104 with chemo before and after surgery for lung cancer
This trial studies AK104 along with chemotherapy given before surgery and after surgery for people with resectable (operable) stage II to IIIA non-small cell lung cancer. It aims to improve treatment effectiveness by shrinking the tumor before surgery and helping prevent it from coming back afterward.
Zhengzhou, HenanAges 18–75
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable non-small cell lung cancer?
- Yes. Clin2 currently lists 355 recruiting resectable non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.